header advert
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

O1265 SELF-REINFORCED POLYLEVOLACTIC ACID IMPLANT FIXATION FOR ARHTRODESES IN RHEUMATOID ARTHRITIS AND ANKLE FRACTURES- A LONG-TERM STUDY



Abstract

Aims: Bioabsorbable self-reinforced polylevolactide (SR-PLLA) fixation devices have been used for several indications within orthopaedics and traumatology since the eighties, but their long-term effects in clinical use and in patients with rheumatoid arthritis (RA), however, are not wellknown, and were evaluated at the present study. Methods: Arthrodeses were fixed with SR-PLLA devices in 27 patients with RA (32 procedures: 22 of the wrist with rods, 7 of the talocal-caneal-calcaneocuboid-talonavicular (triple) and 3 of the talocrural (ankle) with screws and rods) and 16 ankle fractures with screws and/or rods. Outcomes were assessed clinically and radiographically in the long-term (mean 6.0, range 1.1–11.7 years). Computed tomography (CT) evaluation of the implants in a subgroup of 33 patients was performed. Results: All but one wrist fusion, 5/7 of triple fusions, 1 of 3 ankle fusions and all ankle fractures united. Functional results were generally good. In 5 ankle fractures degrading polymer material originating from uncut screw heads led to tissue reactions, and in 2 cases to exceptionally slow degradation. Conclusions: SR-PLLA implants served well as fixation devices for wristand triple arthrodeses in patients with RA and for ankle fractures. Difficulties occurred in bony healing of ankle arthrodeses. The SR-PLLA implants showed high biocompatibility as long as the correct operative technique was followed. Inside the bone, SR-PLLA implants degraded in 4 to 6 years. Slight bone resorption occurred.

Theses abstracts were prepared by Professor Dr. Frantz Langlais. Correspondence should be addressed to him at EFORT Central Office, Freihofstrasse 22, CH-8700 Küsnacht, Switzerland.